Insulin-like growth factor-binding protein 2 in tumorigenesis: Protector or promoter?

Cancer Research

Volumn 61, Issue 24, 2001, Pages 8601-8610

  Hoeflich, Andreas ^a   Reisinger, Raquel ^a   Lahm, Harald ^a   Wolf, Eckhard ^a   Kiess, Wieland ^b   Blum, Werner F ^c   Kolb, Helmut J ^d   Weber, Matthias M ^e  

^a Genzentrum   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d Munich Municipal Hospital   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

CANCER; CANCER GROWTH; CARCINOGENESIS; GENE INACTIVATION; GROWTH REGULATION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NEOPLASMS;

EID: 0035893392     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. Insulin-like growth factor receptors and binding proteins
2. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
3. IGF-independent actions of the IGF binding proteins
4. Insulin-like growth factor I (IGF-I) and long R(3)IGF-I differently affect development and messenger ribonucleic acid abundance for IGF-binding proteins and type I IGF receptors in in vitro produced bovine embryos
5. Gene expression of the six insulin-like growth factor binding proteins in the mouse conceptus during mid- and late gestation
6. The IGF system during fetal-placental development of the mouse
7. Clinical studies of IGFBP-2 by radioimmunoassay
8. The insulin-like growth factor-binding protein (IGFBP) superfamily
9. Altered growth of mice divergently selected for body weight is associated with complex changes in the growth hormone/insulin-like growth factor system
10. Genome-wide search for loci controlling serum IGF binding protein levels of mice
11. Targeted disruption of IGFBP-2 gene
12. Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family
13. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene
14. Overexpression of insulin-like growth factorbinding protein-2 in transgenic mice reduces postnatal body weight gain
15. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins
16. Effects of IGFBP-2 overexpression in vitro and in vivo
17. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2
18. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients
19. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer
20. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: Possible association with the metastatic potential of the tumor
21. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors
22. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer
23. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor
24. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
25. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia
26. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia
27. Insulin-like growth factor-binding protein-2 levels in pediatric patients with growth hormone deficiency, eating disorders and acute lymphoblastic leukemia
28. Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term growth in children with acute lymphoblastic leukaemia
29. The insulin-like growth factors and their binding proteins in a case of non-islet-cell tumour-associated hypoglycaemia
30. Can "big" insulin-like growth factor 11 in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?
31. Characterization of insulin-like growth factor 11 (IGF-II) and IGF binding proteins in patients with non-islet-cell tumor hypoglycemia
32. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms’ tumour
33. Relationship between carbohydrate metabolism and serum insulinlike growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls
34. Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: A molecular mechanism associating endometrial cancer with its risk factors
35. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer
36. Circulating insulin-like growth factor II and colorectal adenomas
37. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women
38. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
39. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia
40. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays
41. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study
42. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
43. Insulin-like growth factor 2 and insulin-like growth factor binding protein 2 expression in hepatoblastoma
44. Growth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-binding protein (IGFBP)-2 gene expression in spleens of juvenile rats
45. The effect of growth hormone treatment on the insulin-like growth factor axis in a child with nonislet cell tumor hypoglycemia
46. Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women
47. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia
48. Insulin-like growth factor-I and insulin stimulate the synthesis of IGF-binding protein-2 in a human embryonic kidney cell line
49. Regulation of insulinlike growth factor (IGF) binding proteins in transgenic mice with altered expression of growth hormone and IGF-I
50. Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: Yield, receptor binding, mitogenic activity, and effects on IGF-binding proteins
51. Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: Endocrine changes and effects on body and organ growth
52. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice
53. In vivo regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin
54. Human granulosa contain messenger ribonucleic acids encoding insulin-like growth factor-binding proteins (IGFBPs) and secrete IGFBPs in culture
55. Insulin-like growth factor-binding protein-2: The effect of human chorionic gonadotropin on its gene regulation and protein secretion and its biological effects in rat Leydig cells
56. Insulin-like growth factor binding protein-2 and -4 messenger ribonucleic acid expression in bovine ovarian follicles: Effect of gonadotropins and developmental status
57. Differential regulation by TGF-β1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells
58. Growth factor regulation of insulin-like growth factor (IGF) binding proteins (IGFBP) and preadipocyte differentiation in porcine stromal-vascular cell cultures
59. Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1
60. Estradiol and progesterone regulate the expression of insulin-like growth factor-I receptor and insulin-like growth factor binding protein-2 in the hypothalamus of adult female rats
61. Glucocorticoid-induced growth arrest of lung alveolar epithelial cells is associated with increased production of insulin-like growth factor binding protein-2
62. Hormonal regulation of IGF-binding protein-2 expression in proliferating C2C12 myoblasts
63. Regulation of insulin-like growth factors I and II and their binding proteins in human bone marrow stromal cells by dexamethasone
64. Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes
65. Regulation of hepatic expression of IGF I and fetal IGF binding protein mRNA in streptozotocin-diabetic rats
66. Structure of the human insulin-like growth factor binding protein-2 gene
67. Genomic structure and regulation of the promoter of the rat insulin-like growth factor binding protein-2 gene
68. Three clustered Spl sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat
69. Cloning of the rat insulin-like growth factorbinding protein-2 gene and identification of a functional promoter lacking a TATA box
70. The unique endometrial expression and genomic organization of the porcine IGFBP-2 gene
71. Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene
72. A distal regulatory region of the insulin-like growth factor binding protein-2 (IGFBP-2) gene interacts with the basic helix-loop-helix transcription factor, AP-4
73. Transactivation of the IGFBP-2 promoter in human tumor cell lines
74. Role for NF-κB in mediating the effects of hyperoxia on IGF-binding protein 2 promoter activity in lung alveolar epithelial cells
75. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers
76. Expression of insulin-like growth factor binding protein 1-6 genes in adrenocortical tumors and pheochromocytomas
77. Evaluation of plasma insulinlike growth factor binding protein-2 as a marker for adrenocortical tumors
78. Insulin-like, growth factor receptors in normal and tumorous adult human adrenocortical glands
79. mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells
80. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues
81. Insulin-like growth factor binding proteins in human breast cancer tissue
82. Effects of estradiol on the expression and production of IGFBP-2 by R3230AC mammary tumor cells
83. Hormonal regulation of insulin-like growth factor 11 and insulin-like growth factor binding protein expression by breast cancer cells in vivo: Evidence for stromal epithelial interactions
84. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins
85. Coordinately up-regulated genes in ovarian cancer
86. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid
87. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
88. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
89. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
90. Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients
91. Production of insulin-like growth factor-binding proteins by human central nervous system tumors
92. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling
93. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques
94. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade
95. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone
96. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues
97. Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms’ tumors
98. Production of insulin-like growth factor binding proteins by small-cell lung cancer cell lines
99. Insulin-like growth factor binding protein expression in human small cell lung cancer cell lines
100. Expression of insulin-like growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines
101. IGFBP-2: An important regulator of insulin-like growth factor action in human lung tumours?
102. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation
103. Expression of IGF-II and IGF binding proteins in differentiating human intestinal Caco-2 cells
104. Expression of IGF-II and IGF-binding proteins by colon cancer cells in relation to growth response to IGFs
105. Insulin-like growth factor binding protein profile secreted by human intestinal epithelial cells varies with polarity
106. Profile of IGF-binding proteins secreted by intestinal epithelial cells changes with differentiation
107. Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells
108. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: Role of IGF-II
109. Differential secretory polarity of IGFBP-6 vervus IGFBP-2 and IGFBP-4 in human intestinal epithelial cells: Is it a way of modulating IGF-II bioavailability towards the IGF-responsive basolateral surface?
110. Prevention of apoptosis by insulin-like growth factor (IGF)-I and [GF-II is differentially attenuated by IGF-binding proteins in PC12 cells
111. Establishment and characterization of a human adrenocortical carcinoma xenograft model
112. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line
113. Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R
114. Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines
115. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status
116. Identification of insulin-like growth factor binding proteins in breast cancer cells
117. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium
118. Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells
119. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer
120. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCAP, DU145, and PC-3 cells
121. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation
122. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen
123. Do insulin-like growth factor binding proteins ([GFBPs) modulate the IGF-I growth promoting and differentiating effects in human neuroblastoma cells?
124. IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: Its production is both IGF- and cell density,-dependent
125. Human neuroblastoma cells use either insulin-like growth factor-1 or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: Variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation
126. Correlation of glioma cell regression with inhibition of insulinlike growth factor 1 and insulin-like growth factor-binding protein-2 expression
127. Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP-4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells
128. A quantitative assay for IGF-I and IGF binding protein mRNAs: Expression in malignant melanoma cells
129. Insulin-like growth factor binding protein production in human follicular thyroid carcinoma cells
130. IGF-II, IGF-binding proteins, and IGF receptors in pancreatic β-cell lines
131. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
132. Insulin-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines
133. Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression
134. Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells
135. Identification and characterization of insulin-like growth factor (IGF) binding protein expression and secretion by adult human adrenocortical cells: Differential regulation by IGFs and adrenocorticotropin
136. Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines
137. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line
138. IGF-I and retinoic acid regulate the distribution pattern of IGFBPs synthesized by the canine mammary tumor cell line CMT-U335
139. Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid
140. Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: Synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells
141. Inhibition of cellular proliferation and modulation of insulin-like growth factor binding proteins by retinoids in a bovine mammary epithelial cell line
142. Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro
143. Phorbol esters differentially regulate the expression of insulin-like growth factor-binding proteins in endometrial carcinoma cells
144. Platelet-activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line (HEC-IA)
145. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
146. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins
147. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells
148. Expression and down-regulation by retinoic acid of IGF binding protein-2 and -4 in medium from human neuroblastoma cells
149. N-myc regulation of type 1 insulin-like growth factor receptor in a human neuroblastoma cell line
150. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours
151. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines
152. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors
153. Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: Implications for autocrine growth regulation
154. Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct
155. Overexpression of insulin-like growth factor-binding protein-2 in C6 glioma cells results in conditional alteration of cellular growth
156. Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts
157. Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): Comparison of its structural and functional properties with IGFBP-I
158. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells
159. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line
160. Complex mediation of uterine endometrial epithelial cell growth by insulinlike growth factor-II (IGF-II) and IGF-binding protein-2
161. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity
162. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: Modulation by transforming growth factor-β and retinoic acid
163. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases
164. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix
165. Cell membrane association of insulin-like growth factor binding protein-2 (IGFBP-2) in the rat brain olfactory bulb
166. 1-integrin of Ewing sarcoma cells
167. Intracellular signalling of insulin-like growth factor binding protein-2
168. Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells
169. Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SH neuroblastoma cells
170. Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells
171. Insulin-like growth factors and their binding proteins in human colonocytes: Preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers
172. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells
173. Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells
174. Interactions between bcl-2 and the IGF system control apoptosis in the developing mouse brain
175. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
176. Reciprocal positive regulation of hypoxia-inducible factor la and insulin-like growth factor 2
177. Insulin-like growth factors, their binding proteins, and transforming growth factor-β1 in oxidant-arrested lung alveolar epithelial cells
178. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells